JP2024547001A5 - - Google Patents

Info

Publication number
JP2024547001A5
JP2024547001A5 JP2024536189A JP2024536189A JP2024547001A5 JP 2024547001 A5 JP2024547001 A5 JP 2024547001A5 JP 2024536189 A JP2024536189 A JP 2024536189A JP 2024536189 A JP2024536189 A JP 2024536189A JP 2024547001 A5 JP2024547001 A5 JP 2024547001A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
pharmaceutical composition
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024547001A (ja
Filing date
Publication date
Priority claimed from PCT/IB2021/000937 external-priority patent/WO2023111618A1/en
Application filed filed Critical
Priority claimed from PCT/US2022/079509 external-priority patent/WO2023114586A1/en
Publication of JP2024547001A publication Critical patent/JP2024547001A/ja
Publication of JP2024547001A5 publication Critical patent/JP2024547001A5/ja
Pending legal-status Critical Current

Links

JP2024536189A 2021-12-17 2022-11-08 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 Pending JP2024547001A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163291315P 2021-12-17 2021-12-17
PCT/IB2021/000937 WO2023111618A1 (en) 2021-12-17 2021-12-17 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
IBPCT/IB2021/000937 2021-12-17
US63/291,315 2021-12-17
PCT/US2022/079509 WO2023114586A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Publications (2)

Publication Number Publication Date
JP2024547001A JP2024547001A (ja) 2024-12-26
JP2024547001A5 true JP2024547001A5 (cg-RX-API-DMAC7.html) 2025-12-19

Family

ID=84387973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536189A Pending JP2024547001A (ja) 2021-12-17 2022-11-08 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法

Country Status (8)

Country Link
US (1) US20250051427A1 (cg-RX-API-DMAC7.html)
EP (1) EP4448005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547001A (cg-RX-API-DMAC7.html)
KR (1) KR20240115910A (cg-RX-API-DMAC7.html)
AU (1) AU2022410770A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242280A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024007288A (cg-RX-API-DMAC7.html)
WO (1) WO2023114586A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025049938A1 (en) * 2023-08-31 2025-03-06 Florida Atlantic University Board Of Trustees Non-invasive delivery method of antibodies to the brain for treatment of brain diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2020023530A2 (en) * 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN112187401B (zh) 2019-07-03 2022-06-14 华为技术有限公司 多时间单元传输方法及相关装置
US11877315B2 (en) 2020-09-15 2024-01-16 Qualcomm Incorporated Wireless device digital beamforming capability indication

Similar Documents

Publication Publication Date Title
Mallah et al. Anti-inflammatory and neuroprotective agents in clinical trials for CNS disease and injury: where do we go from here?
Wisniewski et al. Amyloid-β immunisation for Alzheimer's disease
Godyń et al. Therapeutic strategies for Alzheimer’s disease in clinical trials
Sun et al. Review of drugs for Alzheimer's disease
Gandy et al. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress
JP2024112859A5 (cg-RX-API-DMAC7.html)
JP5349297B2 (ja) ペプチド免疫応答増強方法
JP2014114288A5 (cg-RX-API-DMAC7.html)
JP2025510295A5 (cg-RX-API-DMAC7.html)
DK2758061T3 (en) COMBINATION OF ANTIBIOTICS FOR TREATING AN AUTO-IMMUNE DISORDER
JP2018530574A5 (cg-RX-API-DMAC7.html)
JP2021532126A5 (cg-RX-API-DMAC7.html)
JP2023527542A5 (cg-RX-API-DMAC7.html)
JP2024525559A5 (cg-RX-API-DMAC7.html)
JP2023513220A5 (cg-RX-API-DMAC7.html)
Dai et al. Amyloid-beta targeted therapeutic approaches for Alzheimer’s disease: long road ahead
JP2019519584A5 (cg-RX-API-DMAC7.html)
Luca et al. A Phase 1 single-ascending-dose trial in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of intravenous pnt001, a novel mid-domain tau antibody targeting cis-pT231 tau
Narang et al. Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single‐centre pilot study.
ES3006014T3 (en) Use of nalfurafine for the treatment of demyelinating diseases
Mascarella et al. The ultimate guide to the anti-CGRP monoclonal antibodies galaxy
Vijayakumar et al. Slowing Parkinson’s disease progression with vaccination and other immunotherapies
JP2025515076A5 (cg-RX-API-DMAC7.html)
JP2024532438A5 (cg-RX-API-DMAC7.html)
JP2024540294A5 (cg-RX-API-DMAC7.html)